Abstract:Abstract BACKGROUND AND AIMS Currently >20 000 native peptides in urine are known that are highly dynamic and able to display the status of different organs, especially the kidney. The characterization of urinary peptide profiles (UPP) enables the depiction of kidney disease severity, progression, fibrosis, and informs about the disease etiology. Advanced machine learning algorithms enable combining the changes in the very complex UPP associated with specific disease etiologies and reducing the dataspace to only few dimensions. Here, we show the application of a supervised machine learning pipeline for the visualization of different CKD etiologies based on high-dimensional peptidomics data, toward non-invasive disease classification. METHOD The Uniform Manifold Approximation and Projection (UMAP) algorithm was used as a novel nonlinear dimensionality-reduction technique to visualize and differentiate the UPP of patients with CKD of different etiologies. UPP of individual CKD patients (with diabetic kidney disease DKD, (n = 386), IgA nephropathy (n = 743) and vasculitis (n = 150)) and 369 healthy controls were extracted from the Human Urinary Proteome Database which contains >85 000 proteomics datasets analyzed using capillary electrophoresis coupled mass spectrometry. About 80% of the extracted datasets were used as a training and 20% as validation set. RESULTS When applying supervised-UMAP to the DKD patient and control datasets, excellent separation with an F1 score of 99.5% ± 0.9% in the training set, and 93.1% ± 3.3% in the independent test set could be observed. Subsequently, this approach was applied to differentiate controls and three kidney diseases (DKD, IgA nephropathy and vasculitis) simultaneously. In the training set an accuracy of up to 98% in DN and controls, and an overall F1 score of 93.7% ± 2.3% (Figure) was achieved. In the independent test set, accuracy decreased as expected to around 90% for controls, 83.8% for IgA nephropathy, 79.2% for DKD and 66.7% for vasculitis. The overall F1 score in the test set is 81.9% ± 2.2%. Of note, controls (n = 369) were consistently classified with the highest accuracy across all groups, the disease with smallest sample size (vasculitis, n = 150) always showed the lowest accuracy. A substantial proportion of vasculitis was classified as IgA nephropathy, which has the largest sample size of n = 743. For the validation of the pipeline the permutation test was used. Permutation test was repeated 100 times using all the samples of CKD -free controls and three kidney diseases. The resulted scores were normally distributed, with a mean of 32.5% and standard deviation of 1.2%. Compared with the true F1 score, which was calculated as 81.9% from above, the probability of obtaining such a high score by chance is very low (P < 0.01). CONCLUSION We show that UMAP combined with supervised machine learning applied to high dimensional peptidomics data, enables distinguishing multiple kidney diseases with good accuracy and with very small standard deviation between multiple train-test splits. To our knowledge, our study is the first of its kind to reduce the complexity of the urinary peptidome to a single point in space, and categorize disease etiology based on the spatial information. The approach presented has the potential to enable non-invasive differential diagnosis of kidney disease etiologies. To improve accuracy of this non-invasive method, inclusion of additional clinical parameters will be tested.

Evaluation of the reliability of MS1‐based approach to profile naturally occurring peptides with clinical relevance in urine samples

Urine Proteomics Identifies Biomarkers for Diabetic Kidney Disease at Different Stages

Urinary Proteome Analysis by Matrix-Assisted Laser Desorption/Ionization Time-Of-Flight Mass Spectrometry with Magnetic Beads for Identifying the Pathologic Presentation of Clinical Early Iga Nephropathy

Analysis of Urinary Proteomic Patterns for Diabetic Nephropathy by ProteinChip.

Reproducibility Evaluation of Urinary Peptide Detection Using CE-MS

Amino Acid Profile Determination in the Urine of Bladder Cancer Patients by Ce-Ms with On-Line Ph-Mediated Stacking and Pattern Recognition

A Rapid and Sensitive Single-Cell Proteomic Method Based on Fast Liquid-Chromatography Separation, Retention Time Prediction and MS1-only Acquisition.

Identification of the Pathologic Presentation of Clinical Early IgA Nephropathy by MALDI-TOF-MS with Magnetic Beads

MO386: Visualising and Differentiating Kidney Disorders by Urinary Peptidomics Using a Machine Learning Approach

Urinary peptidomic liquid biopsy for non-invasive differential diagnosis of chronic kidney disease

Targeted MRM Quantification of Urinary Proteins in Chronic Kidney Disease Caused by Glomerulopathies

Integration of metabolomics and peptidomics reveals distinct molecular landscape of human diabetic kidney disease

Deep Coverage in Identification of Proteome Based on Separation by Multi-dimensional Liquid Chromatography

Multitargeted Internal Calibration for the Quantification of Chronic Kidney Disease-Related Endogenous Metabolites Using Liquid Chromatography-Mass Spectrometry

Urine-HILIC: Automated Sample Preparation for Bottom-Up Urinary Proteome Profiling in Clinical Proteomics

Sheathless CE-MS based metabolic profiling of kidney tissue section samples from a mouse model of Polycystic Kidney Disease

Simultaneous determination of multiple urine biomarkers for kidney injury using SPE combined with LC-MS/MS

Integration of Urinary Peptidome and Fecal Microbiome to Explore Patient Clustering in Chronic Kidney Disease

LC-MS-based serum metabolic profiling for genitourinary cancer classification and cancer type-specific biomarker discovery.

Advancing Serum Peptidomic Profiling by Data-Independent Acquisition for Clear-Cell Renal Cell Carcinoma Detection and Biomarker Discovery.

Robust Capillary- and Micro-Flow Liquid Chromatography-Tandem Mass Spectrometry Methods for High-Throughput Proteome Profiling